the TTRACK investigators2026-01-282026-01-282024-12the TTRACK investigators 2024, 'Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy', ESC Heart Failure, vol. 11, no. 6, pp. 4314-4324. https://doi.org/10.1002/ehf2.149712055-5822PubMedCentral: PMC11631301https://hdl.handle.net/10641/7734Publisher Copyright: © 2024 Pfizer Inc. and The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.11653631enginfo:eu-repo/semantics/openAccessCardiac amyloidosisEpidemiologyHypertrophyPrevalenceTransthyretin amyloid cardiomyopathyCardiology and Cardiovascular MedicineJournal ArticleMulticenter StudyYesyes/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article10.1002/ehf2.14971https://www.scopus.com/pages/publications/85202614642https://www.scopus.com/pages/publications/85202614642#tab=citedBy